SCHEMBL3011340

SCHEMBL3011340

COc1ccc(OC)c(S(=O)(=O)C2CCN(c3nc(-c4c(C)cc(C)cc4C)cs3)CC2)c1

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 5/20 0.46
SMN1; SMN2 Q16637 3/20 0.46
MAPT P10636 6/20 0.42
REV1 Q9UBZ9 1/20 0.41
NPC1 O15118 4/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
ALDH1A1 P00352 4/20 0.39
RECQL P46063 2/20 0.39
HSD17B10 Q99714 3/20 0.39
LMNA P02545 3/20 0.39
TDP1 Q9NUW8 1/20 0.39
USP2 O75604 1/20 0.39
TP53 P04637 1/20 0.39
TSHR P16473 1/20 0.39
MAPK1 P28482 1/20 0.39
HPGD P15428 1/20 0.38
AR P10275 1/20 0.38
HTT P42858 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3023026 0.93 RAB9A (0.48) RAB9ASMN1; SMN2MAPTREV1NPC1
SCHEMBL3005809 0.93 RAB9A (0.43) RAB9ASMN1; SMN2MAPTREV1NPC1
SCHEMBL3021480 0.90 SMN1; SMN2 (0.41) RAB9ASMN1; SMN2MAPTNPC1ALDH1A1
SCHEMBL3017129 0.90 RAB9A (0.40) RAB9ASMN1; SMN2MAPTNPC1L3MBTL1
SCHEMBL3012788 0.90 SMN1; SMN2 (0.51) RAB9ASMN1; SMN2MAPTREV1NPC1
SCHEMBL3015674 0.88 SMN1; SMN2 (0.56) RAB9ASMN1; SMN2MAPTNPC1ALDH1A1
SCHEMBL3014461 0.88 AR (0.52) RAB9ASMN1; SMN2MAPTREV1NPC1
SCHEMBL3004108 0.87 SMN1; SMN2 (0.48) RAB9ASMN1; SMN2MAPTNPC1L3MBTL1
SCHEMBL3002190 0.87 SMN1; SMN2 (0.61) RAB9ASMN1; SMN2MAPTNPC1ALDH1A1
SCHEMBL3016944 0.87 REV1 (0.54) RAB9ASMN1; SMN2MAPTREV1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA RAB9A 2943/4885SMN1; SMN2 1/4885MAPT 18/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.